Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04300036
Other study ID # 829/62
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 1, 2020
Est. completion date February 10, 2021

Study information

Verified date March 2020
Source Chulalongkorn University
Contact Pornanong Aramwit, Ph.D
Phone +66899217255
Email aramwit@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this study were to evaluate efficacy and safety of longan syrup in healthy volunteers with insomnia. Subjects will take 15 ml of longan syrup once a day for 3 months. They will be investigated their insomnia using Insomnia Severity Index (ISI) questionnaire, Thai- The Pittsburgh Sleep Quality Index (PSQI) questionnaire,STOP - BANG questionnaire, Epworth Sleepiness Scale (ESS) questionnaire, Actiwatch, plasma cortisol, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), creatinine (Cr), blood urea nitrogen (BUN), fasting blood sugar, HbA1C, complete blood count (CBC), hemoglobin, lipid profile, phosphate level, saliva cortisol, and urine melatonin before and after taken longan syrup.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date February 10, 2021
Est. primary completion date January 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria:

- Age 35-65 years

- Insomnia severity index (ISI) more than 7

- Thai- The Pittsburgh Sleep Quality Index (PSQI)) more than 5

- STOP - BANG less than 5

- No diabetes mellitus and thyroid dysfunction

- Fasting plasma glucose less than 126mg/dl

- Can communication (reading and writing)

- Be willing to be subjects in this study

Exclusion Criteria:

- Know longan allergy or have history of adverse events from longan

- Take benzodiazepine, melatonin, valerian, and St Johns Wort in 1 month before this study starting

- Take medicines, herbs, or food supplements including thiazide diuretics, beta-blockers ,and estrogen that have an effect on blood sugar level in 1 month before this study starting

- Cannot control comorbidity diseases

- Irregular working hours

- Pregnancy or breast feeding

- Participated in other studies

Study Design


Related Conditions & MeSH terms

  • Insomnia
  • Sleep Initiation and Maintenance Disorders

Intervention

Dietary Supplement:
longan syrup
Subjects will take 15 ml of longan syrup once a day for 3 months
Placebo syrup
Subjects will take 15 ml of placebo syrup once a day for 3 months

Locations

Country Name City State
Thailand Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn Unviersity Bangkok

Sponsors (1)

Lead Sponsor Collaborator
Chulalongkorn University

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Insomnia severity index Insomnia severity index after taken longan syrup will be less than before taken. The minimum and maximum values are 0 and 28 scores, respectively. Higher scores mean a worse outcome. 3 months
Secondary Thai- The Pittsburgh Sleep Quality Index Thai- The Pittsburgh Sleep Quality Index after taken longan syrup will be less than before taken. The minimum and maximum values are 0 and 21 scores, respectively. Higher scores mean a worse outcome. 3 months
Secondary Snoring, Tiredness, Observed apnea, blood Pressure, Body mass index, Age, Neck circumference and Gender questionaire Snoring, Tiredness, Observed apnea, blood Pressure, Body mass index, Age, Neck circumference and Gender questionaire (STOP - BANG) after taken longan syrup will not be more than before taken. The minimum and maximum values are 0 and 8 scores, respectively. Higher scores mean a worse outcome. 3 months
Secondary Epworth sleepiness scale Epworth sleepiness scale after taken longan syrup will be less than before taken. The minimum and maximum values are 0 and 24 scores, respectively. Higher scores mean a worse outcome. 3 months
Secondary Actiwatch value Actiwatch value after taken longan syrup will be better than before taken. 3 months
Secondary Serum cortisol Serum cortisol value at 8.00 o'clock (normal value 5-23 mcg/dL) after taken longan syrup will not be less than before taken. 3 months
Secondary Saliva cortisol Saliva cortisol at 20.00 o'clock (normal value 3.9 +/- 0.2 nmol/L (range 2.2-4.1 nmol/L)) after taken longan syrup will not be more than before taken. 3 months
Secondary Urine Melatonin Urine Melatonin overnight (in ng/mL) after taken longan syrup will not be less than before taken. 3 months
Secondary Serum Low-density lipoprotein Serum Low-density lipoprotein (in mg/dL) after taken longan syrup will not be more than before taken. 3 months
Secondary Serum High-density lipoprotein Serum High-density lipoprotein (in mg/dL) after taken longan syrup will not be more than before taken. 3 months
Secondary Serum total cholesterol Serum total cholesterol (in mg/dL) after taken longan syrup will not be more than before taken. 3 months
Secondary Serum triglyceride Serum triglyceride (in mg/dL) after taken longan syrup will not be more than before taken. 3 months
Secondary Glycohemoglobin Glycohemoglobin (Hemoglobin A1c) (in %) after taken longan syrup will not be more than before taken. 3 months
Secondary Fasting plasma glucose Fasting plasma glucose (in mg/dL) after taken longan syrup will not be more than before taken. 3 months
Secondary Aspartate aminotransferase in serum Aspartate aminotransferase (in U/L ) after taken longan syrup will not be more than before taken. 3 months
Secondary Alanine aminotransferase in serum Alanine aminotransferase (in U/L ) after taken longan syrup will not be more than before taken. 3 months
Secondary Alkaline phosphatase in serum Alkaline phosphatase (in U/L ) after taken longan syrup will not be more than before taken. 3 months
Secondary Serum creatinine Serum creatinine (in mg/dl ) after taken longan syrup will not be more than before taken. 3 months
Secondary Blood Urea Nitrogen Blood Urea Nitrogen (in mg/dl ) after taken longan syrup will not be more than before taken. 3 months
Secondary Hemoglobin Hemoglobin (in g/dl ) after taken longan syrup will not be more than before taken. 3 months
Secondary Phosphate level Phosphate level (in g/dl ) after taken longan syrup will not be more than before taken. 3 months
Secondary Complete blood count Complete blood count (in 10^6 cells/mcl ) after taken longan syrup will not be more than before taken. 3 months
See also
  Status Clinical Trial Phase
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT05963542 - Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia N/A
Completed NCT06339853 - Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia N/A
Recruiting NCT04069247 - Effectiveness of eCBT-I on Improving Mental Health in Chinese Youths With Insomnia N/A
Completed NCT04493593 - Internet-delivered CBT-I (Space for Sleep): Pilot and Feasibility N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Recruiting NCT06278077 - Neurexan - a Clinical Trial in Short-Term Insomnia Patients Phase 2
Completed NCT04661306 - The Better Sleep for Supporters With Insomnia Study N/A
Recruiting NCT06207279 - Preliminary Study on the Development and Reliability and Validity of Attention Rating Scale
Recruiting NCT06006299 - Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC) N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT04035200 - Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation Phase 2
Active, not recruiting NCT05027438 - Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention N/A
Recruiting NCT06053840 - An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients With Severe Insomnia Phase 4
Not yet recruiting NCT06348082 - Project Women's Insomnia Sleep Health Equity Study (WISHES) N/A
Not yet recruiting NCT06363799 - Osteopathic Protocol for Insomnia in College Students N/A
Not yet recruiting NCT06025968 - Digital Cognitive-behavioral Therapy for Insomnia for Patients With Multiple Sclerosis N/A
Not yet recruiting NCT05991492 - Improving Sleep With a Digital Cognitive Behavioral Therapy for Insomnia Application N/A